chartexchange

NKGen Biotech Reports Long-Term Clinical Observations with Investigational Alzheimer’s Treatment Troculeucel at CTAD 2026

GlobeNewswire Inc. | Nov 16, 2026 1:05 PM EST

Single patient showed rapid and sustained improvement in CDR-SB score from 11 (moderate AD) to 7 (mild AD) within three months of treatment, followed by further improved scores consistent with mild AD throughout the remaining nine months on study and subsequent 12-month open-label extension Single patient showed rapid and sustained improvement in CDR-SB score from 11 (moderate AD) to 7 (mild AD) within three months of treatment, followed by further improved scores consistent with mild AD throughout the remaining nine months on study and subsequent 12-month open-label extension

Read original article